Why is overcorrection of hemoglobin discouraged when treating CKD-related anemia?

• A. It increases cardiovascular risk
• B. It decreases cardiovascular risk
• C. It has no impact on outcomes
• D. It improves outcomes in all cases

Answer: (A)

Overcorrecting hemoglobin when treating CKD-related anemia is discouraged because pushing hemoglobin to very high levels increases the risk of cardiovascular problems. The goal is to relieve symptoms and reduce transfusion needs, but not to normalize hemoglobin. When the level is aimed too high, blood becomes more viscous, which raises vascular resistance and can elevate blood pressure. That extra workload on the heart can worsen or trigger left ventricular hypertrophy, heart failure, and other cardiac events. In addition, higher hemoglobin targets often require larger doses of erythropoiesis-stimulating agents, and those higher doses have been linked to more thrombotic events such as heart attack and stroke, as well as death in some studies. Trials comparing higher versus lower targets consistently showed more adverse cardiovascular outcomes with aggressive correction, leading to guideline recommendations to maintain hemoglobin in a lower, safer range (roughly around 10–11.5 g/dL) and to avoid rapid or excessive increases. So, the reason overcorrection is discouraged is that it can increase cardiovascular risk rather than improve outcomes.